Helius Medical Technologies (OTCMKTS:HSDT) released its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.04, Bloomberg Earnings reports.
Shares of HSDT traded down $0.05 during midday trading on Friday, hitting $0.47. 761,700 shares of the stock were exchanged, compared to its average volume of 753,423. The stock has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $0.56. Helius Medical Technologies has a 52-week low of $0.25 and a 52-week high of $2.18.
A number of analysts have commented on HSDT shares. Oppenheimer reaffirmed a “hold” rating on shares of Helius Medical Technologies in a research report on Wednesday. Zacks Investment Research lowered shares of Helius Medical Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, July 15th.
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Read More: Cost of equity and a company’s balance sheet
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.